{"title":"通过自身白细胞免疫加强慢性乙型肝炎的抗病毒治疗。","authors":"Oleksandr B Herasun","doi":"10.2174/1872214812666180507095457","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The article presents a new method of intensification of antiviral therapy for chronic hepatitis B with intradermal autoleukocyte immunization during treatment with a drug of nucleotide analogues - tenofovir (patent UA 113873 U, 2017); other curative vaccines for chronic hepatitis B are also regarded.</p><p><strong>Objective: </strong>The research involves patients with chronic hepatitis B (30), whose replication of HBV DNA decreased to a certain level after long-lasting (over 2 years) antiviral therapy, its further reduction ceased. These patients underwent intradermal autoleukocyte immunization for intensification of antiviral therapy.</p><p><strong>Method: </strong>Leukocytes were isolated from plasma of a patient's heparinized venous blood by centrifuging at 400 g for 8 minutes, after that the precipitate was resuspended in 1-1.5 ml of own blood serum and injected intradermally into the back in the dose 0.1 ml. Immunization was conducted at least 3 times with 30-40-day interval.</p><p><strong>Results: </strong>Due to autoleukocyte immunization, the process of further decrease in virus reproduction resumed in 24 patients (out of 30; 80%). Out of six other patients (20%), in whom HBV DNA was detected only by supersensitive PCR method (sensitivity to 5 IU/ml) after long-lasting antiviral therapy, a negative result on examination was achieved in 2 individuals (33.33%).</p><p><strong>Conclusion: </strong>Autoleukocyte immunization intensifies efficiency of antiviral therapy for chronic hepatitis B with a drug from the group of nucleotide analogues.</p>","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Intensification of antiviral therapy for chronic hepatitis B with autoleukocyte immunization.\",\"authors\":\"Oleksandr B Herasun\",\"doi\":\"10.2174/1872214812666180507095457\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The article presents a new method of intensification of antiviral therapy for chronic hepatitis B with intradermal autoleukocyte immunization during treatment with a drug of nucleotide analogues - tenofovir (patent UA 113873 U, 2017); other curative vaccines for chronic hepatitis B are also regarded.</p><p><strong>Objective: </strong>The research involves patients with chronic hepatitis B (30), whose replication of HBV DNA decreased to a certain level after long-lasting (over 2 years) antiviral therapy, its further reduction ceased. These patients underwent intradermal autoleukocyte immunization for intensification of antiviral therapy.</p><p><strong>Method: </strong>Leukocytes were isolated from plasma of a patient's heparinized venous blood by centrifuging at 400 g for 8 minutes, after that the precipitate was resuspended in 1-1.5 ml of own blood serum and injected intradermally into the back in the dose 0.1 ml. Immunization was conducted at least 3 times with 30-40-day interval.</p><p><strong>Results: </strong>Due to autoleukocyte immunization, the process of further decrease in virus reproduction resumed in 24 patients (out of 30; 80%). Out of six other patients (20%), in whom HBV DNA was detected only by supersensitive PCR method (sensitivity to 5 IU/ml) after long-lasting antiviral therapy, a negative result on examination was achieved in 2 individuals (33.33%).</p><p><strong>Conclusion: </strong>Autoleukocyte immunization intensifies efficiency of antiviral therapy for chronic hepatitis B with a drug from the group of nucleotide analogues.</p>\",\"PeriodicalId\":89474,\"journal\":{\"name\":\"Recent patents on endocrine, metabolic & immune drug discovery\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-05-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Recent patents on endocrine, metabolic & immune drug discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1872214812666180507095457\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on endocrine, metabolic & immune drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1872214812666180507095457","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Intensification of antiviral therapy for chronic hepatitis B with autoleukocyte immunization.
Introduction: The article presents a new method of intensification of antiviral therapy for chronic hepatitis B with intradermal autoleukocyte immunization during treatment with a drug of nucleotide analogues - tenofovir (patent UA 113873 U, 2017); other curative vaccines for chronic hepatitis B are also regarded.
Objective: The research involves patients with chronic hepatitis B (30), whose replication of HBV DNA decreased to a certain level after long-lasting (over 2 years) antiviral therapy, its further reduction ceased. These patients underwent intradermal autoleukocyte immunization for intensification of antiviral therapy.
Method: Leukocytes were isolated from plasma of a patient's heparinized venous blood by centrifuging at 400 g for 8 minutes, after that the precipitate was resuspended in 1-1.5 ml of own blood serum and injected intradermally into the back in the dose 0.1 ml. Immunization was conducted at least 3 times with 30-40-day interval.
Results: Due to autoleukocyte immunization, the process of further decrease in virus reproduction resumed in 24 patients (out of 30; 80%). Out of six other patients (20%), in whom HBV DNA was detected only by supersensitive PCR method (sensitivity to 5 IU/ml) after long-lasting antiviral therapy, a negative result on examination was achieved in 2 individuals (33.33%).
Conclusion: Autoleukocyte immunization intensifies efficiency of antiviral therapy for chronic hepatitis B with a drug from the group of nucleotide analogues.